The evaluation of potential human carcinogens: A histopathologist's point of view

Experimental and Toxicologic Pathology

Volumn 48, Issue 2-3, 1996, Pages 169-174

  Greaves, Peter ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Carcinogens, human, evaluation; Evaluation, carcinogens

Indexed keywords

N (2 FLUORENYL)ACETAMIDE; PHENOBARBITAL; TAMOXIFEN;

ANIMAL MODEL; CHEMICAL CARCINOGENESIS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG TOXICITY; HOMEOSTASIS; LIVER CANCER; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION;

ANIMALIA; RODENTIA;

EID: 0029875995     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0940-2993(96)80038-8     Document Type: Conference Paper

References (17)

1. BRAND KG, JOHNSON KH, BUOEN LC: Foreign body tumorigenesis. CRC Crit Rev Toxicol 1976; 4: 353-394.
2. DAVIES TS, MONRO A: Marketed human pharmaceuticals reported to be tumorigenic in rodents. J Am Coll Toxicol 1995; 14: 90-107.
3. FARBER E: Cancer development as viewed by a pathologist: A different perspective. Mod Pathol 1988; 1: 2-3.
4. FARBER E, RUBIN H: Cellular adaptation in the origin and development of cancer. Cancer Res 1991; 51: 2751-2761.
5. DE SOUZA AT, HANKINS GR, WASHINGTON MK, et al.: M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nature Genetics 1995; 11: 447-449.
6. GRASSO P: Persistent organ damage and cancer production in rats and mice. Arch Toxicol 1987; suppl. 11: 75-83.
7. GREAVES P, GOONETILLEKE R, NUNN G, et al.: Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 1993; 53: 3919-3924.
8. HAN Y, LIEHR JG: Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 1992; 52: 1360-1363.
9. HASEMAN JK, SEILKOP SK: An examination of the association between maximum-tolerated dose and carcinogenicity in 326 long-term studies in rats and mice. Fund Appl Toxicol 1992; 19: 207-213.
10. JIRTLE RL: Liver tumor promotion: A process of natural selection. In: COCKBURN A, SMITH L (eds.): Nongeotoxic carcinogenesis. Tenth Workshop of the Ernst Schering Research Foundation, Springer 1994; pp. 157-172.
11. JIRTLE RL, HANKINS GR, REISENBICHLER H, et al.: Regulation of mannose 6-phosphate/insulin-like growth factor-II receptors and transforming growth factor beta during liver tumor promotion with phenobarbital. Carcinogenesis 1994; 15: 1473-1478.
12. LORD PG, HARDAKER KJ, LOUGHLIN JM, et al.: Point mutation analysis of ras genes in spontaneous and chemically C57BL/10J mouse liver tumours. Carcinogenesis 1992; 13: 1383-1387.
13. ORTON TC, DOUGHTY SE, KLAINOWSKI AE, et al.: Phenobarbitone induced mouse hepatocyte proliferation is associated with increased EGR- and TGFα expression and reduced TGFβ1 and M6PR expression. Carcinogenesis in press.
14. SARGENT LM, DRAGAN YP, BAHNUB N, et al.: Tamoxifen induces hepatic aneuploidy and mitotic spindle disruption after a single in vivo administration to female Sprague-Dawley rats. Cancer Res 54: 3357-3360.
15. TUCKER MJ, ADAM HK, PATTERSON JS: Tamoxifen. In: LAURENCE DR, MCCLEAN AE, WETHERALL M (eds.): Safety Testing of New Drugs, Laboratory Predictions and Clinical Performance. Academic Press London 1984 pp. 125-161.
16. WOOD M: Factors influencing the induction of tumours of the urinary bladder and liver by 2-acetylaminofluorene in the mouse. Eur J Cancer 1969; 5: 41-47.
17. ZEISE L, CROUCH EAC, WILSON R: A possible relationship between toxicity and carcinosenicity. J Am Coll Toxicol 1986; 5: 137-151.